Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon alfa-2b + ribavirin with or without amantadine in treatment-naive chronic hepatitis C
NL-OMON20761Active, not recruiting
- Sponsor
- Dr. K.J. van Erpecum, hoofdonderzoeker Prof. Dr. M. Samsom, hoofdonderzoker UMC Utrecht Huispostnummer F02.618 Postbus 85500 3508 GA Utrecht
- Start
- Feb 2000
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of amantadine, interferon alfa-2b and ribavirin in hepatitis C virus infection (2 arms), sponsored by Dr. K.J. van Erpecum, hoofdonderzoeker Prof. Dr. M. Samsom, hoofdonderzoker UMC Utrecht Huispostnummer F02.618 Postbus 85500 3508 GA Utrecht. Primary endpoints: Virological response at week 52 and Virological response at week 104. Started Feb 2000; status: active, not recruiting.
02
Drugs
amantadineinterferon alfa-2bribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON20761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20761.